To evaluate the feasibility and effect of intraoperative radiotherapy on patients with borderline resectable pancreatic cancer, Seventy-two consecutive patients who had undergone resection with/without the addition of intraoperative radiotherapy between 2013 and 2017 at our single institution were included and analyzed. Thirty-four patients (47.2%) received additive low-energy photon IORT with 17.4 Gy median radiation dose. With a median follow-up of 20.0 months (range, 6.0-40.0), the media overall survival time and the media progression-free survival time of all patients was 18.1 months and 11.2 months, respectively. Univariate analyses showed that not receiving IORT retained significance with regard to both PFS (HR, 1.74; p=0.02) and OS (HR, 1.79; p=0.02). In the multivariate analysis, not receiving IORT was associated with a lower probability of PFS (HR, 2.13; p<0.01) and OS (HR, 2.05; p<0.01). After resection combined with intraoperative radiotherapy, 20 (86%) of patients treated with surgery with intraoperative radiotherapy completely relieved the abdominal/waist pain, while 11 (44%) of patients of the control group relieved the pain (p=0.01). Thus, IORT can prolong survival and also improve the quality of life, and it can provide an adjunct to resection in patients with borderline resectable pancreatic cancer.
Introduction
Pancreatic Cancer (PC) is the fourth leading cause of cancerrelated deaths in America with an overall 5-year survival rate of 7% [1] , and is likely to be the second cancer cause of death by 2030 [2] . Surgery still remains the most effective treatment at present. However, only 15-20% of the patients were diagnosed in potentially resectable stages, and the rest were locally advanced or metastatic. There is a distinct subset of pancreatic cancer patients named as "Borderline Resectable Pancreatic Cancer (BRPC)", which was characterized by reconstructable venous involvement of the superior mesenteric vein or portal vein, along with abutment but not encasement of arterial structures or removable retroperitoneal structures [3] . Different with resectable PC, patients with BRPC act as the imprecise continuum between straightforwardly resectable and technically unresectable stage, for some degree of vascular involvement that may jeopardize a margin-negative (R0) resection [4] . For this reason, part of the BRPC patients choose to downstage by neoadjuvant therapy. However, some research show that only 24%-46% BRPC patients obtain the opportunity to curative surgical treatment after neoadjuvant therapy [5, 6] . In China, the conversion of successful resection rate was lower due to the fact that most of chinese patients could not tolerate the side effects of neoadjuvant therapy, and many patients tend to choose the traditional Chinese medicine rather than chemotherapy when a tumor cannot be removed surgically. In this case, a surgery-first strategy was very common in China and the final determination of whether a tumor is able to be resected with negative margins has customarily been made by the surgeon undertaking a trial dissection. So, combined a new technology to help achieving a margin-negative (R0) resection is essential.
The development of Intraoperative Radiotherapy (IORT) offers a hope to transform the R1 margin to R0 margin through killing the residual cancer cells in positive surgical margin with a high-dose radiation. INTRABEAM ® PRS500 system (Carl Zeiss, Oberkochen, Germany) is the most widely used mobile intraoperative radiotherapy device to date, and the effect in resectable and locally advanced or unresectable pancreatic cancer has been reported. However, the researches focusing on the role of INTRABEAM IORT for BRPC patients, are unclear. In the current study, we reviewed a retrospective single-institutional series of BRPC patients who received surgical resection combining with/ without sequential IORT. To determine the role of IORT in patient with BRPC, clinicopathological characteristics and survival information from 72 patients with BRPC matching the condition were collected and analyzed.
Materials and Methods

Patients
We retrospectively collected all of cases of patients with pancreatic cancer since January 1, 2013 to June 30, 2017 at the Sun Yat-sen Memorial Hospital of Sun Yat-sen University matching the following standards: 1). BRPC was defined to include one or more of the after radiographic findings: Tumor abutment (>180° of the circumference of the vessel) of the Superior Mesenteric Artery (SMA) or celiac axis; tumor abutment or encasement (>180° of the circumference of the vessel) of a short segment of the hepatic artery, short-segment occlusion of the Superior Mesen-Teric Vein (SMV), Portal Vein (PV), or SMV-PV confluence amenable to vascular resection and reconstruction [7] ; 2). Pancreatic ductal adenocarcinoma was pathologically identified; 3). All patients postoperatively received gemcitabine-based combination chemotherapy. Exclusion criteria was those combining with other types of tumor like islet cell tumor and mucinous cystadenocainoma or metastasis. Finally, we sorted out 72 patients to further analyze the survival and the quality of life, in which 34 patients treated with surgery combined with IORT, while 38 patients treated with surgery only. The study protocol was approved by the institutional ethic committee. Written informed consent on intra-operative radiotherapy was obtained from patients treated with IORT prior to operation.
Procedures
Among of IORT group/non-IORT group, 25/26 patients with tumor in the head of pancreas received pancreatoduoenectomy, and 9/12 patients with tumor in the body or tail of pancreas received distal pancreatectomy combined with splenectomy, respectively. In IORT group, the operations were carried out at an operating room equipped with an intraoperative low-energy photon applicator (Carl Zeiss Intrabeam, X-ray source 50 kV, German) ( Figure 1A ). Patients immediately received the intraoperative radiation after tumor removal ( Figure 1B ) and before digestive anastomosis ( Figure 1C ). The protocol using the intra-operative radiotherapy method in this study was described in previous reports [8] . The target area was 5 mm away from source applicator with a 5cm efficient diameter. The radial field included the tumor bed with approximate 1-cm to 3-cm margin, comprising the retroperitoneum, vascular structures, and tumor bed extending from the transected bile duct superiorly to the right kidney laterally and to the pancreatic remnant medially. Prior to irradiation, lead shielding was used to cover the surrounding radiosensitive organs like small bowel in order to avoid unnecessary damage. The IORT dose was prescribed to 90% isodose and the media dose was 17.4 Gy (range 10 to 20 Gy). The radiation dose depended on the vessel number of tumor involvement, the vessel range of tumor encasement and the possibility and extent of tumor residue after resection. The dose would be reduced to 10 Gy for R0 margins confirmed by frozen section. For larger tumors or tumors involving with main vessels, 20 Gy was preferred. After IORT, surgeons continued to rebuild the digestive tract and finished the operation. All of patients postoperatively received six courses of gemcitabine monotherapy after rest for 4-6 weeks. 
Data Collection
Patient demographics (age and gender), jaundice status, pain, CA 19-9, tumor site, tumor stage (the pathological TNM staging system issued by 8th edition of AJCC), Lymph Node (LN) invasion, vascular invasion, perineural invasion，pathological differentiation was obtained. Margin resection status, Visual Analogue Scale (VAS) at the preoperation and the first postoperative follow-up and postoperation complication were collected. Acute and chronic toxicities were evaluated using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer score.
Follow-Up
The researchers would follow up all of patients every month after operation for the initial 1 year and every 3 months for the next year and every 6 months for 3 additional years thereafter. Patients were restaged routinely every 3 to 6 months with blood tests, ultrasound and Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) of the upper abdomen. Progression was defined as identification of suspicious imaging finding or biopsy-proven tumor in the tumor bed, regional LN area or distant area. Overall survival (OS) was defined as the duration from the date of operation until death or the last follow-up. ProgressionFree Survival (PFS) was defined as the duration from the date of operation until the date when tumor progression was diagnosed or the last follow-up. The last follow-up was completed on June 30 2018.
Statistical Analysis
SPSS version 24 software (SPSS Inc, Chicago, IL, USA) was used to analyze the data. The primary endpoints of the analysis were OS and PFS. Potential associations were assessed in univariate and multivariate analyses using the Cox proportional hazards model (2-tailed p test 0.05). As for the contrast of pain. patients were divided into four subgroups: the mild group (VAS=1-3), severe group (VAS=4-6), extreme severe group (VAS=7-10) and no-pain 
Results
Patient characteristics
Median follow-up time for the entire group of patients was 20.0 months (range: 6.0-40.0 months). No patients were lost to follow-up. Baseline characteristics of patients are shown in (Table  1 
Contrast for overall survival
OS for all patients at 1 year, 2 years and 3 years was 54.2%, 27.8% and 11.1%, respectively (Figure 2A) . The median overall survival of the IORT group is 22.0 mouths (range: 7.9 to 40.1), Figure 2C ) were associated with a higher probability of OS consistently.
Contrast for Progression-free survival
PFS for the study population at 1 year, 2 years and 3 years was 34.7%, 11.1% and 0 ( Figure 2D ). The median PFS of the IORT group/the non-IORT group is 11.7 months (range: 4.7 to 28.4)/8.9 months (range: 1.9 to 33.8) (p<0.01). Univariate analyses revealed a significantly higher risk of R1 resectio (Table 2; p<0.01) ( Figure 2E ) and non-IORT (Table 2, p=0.02) ( Figure 2F ). The multivariate Cox proportional hazard analyses showed R1 resection (Table 3 ; p<0.01) and IORT (Table 3 ; p<0.01) retained significance with regard to PFS. 
Waist/abdominal pain
In pre-operation, the number of the mild group, severe group, extreme severe group and no-pain group of the IORT group were 9(26.4%), 10(29.4%), 4(11.8%) and 11(32.4%). Correspondingly, the number of the non-IORT group were 11(28.9%), 9(23.7%), 5(13.2%), 13(34.2%), respectively. The Kruskal-Wallis Test analyses showed no difference between the two groups (Table 4 ; p =0.82). In postoperation, 20(86%)of the IORT group obtained complete remission of pain vs. 11(44%) of the non-IORT group obtained complete remission of pain. The Kruskal-Wallis Test analyses showed that the difference of pain control between the two groups of pain control makes sense (Table 4 ; p =0.01). 
Complication
In all patients, the rate of operative complications was approximately 57%. The operative complications include bile leakage (n=5), pancreatic leakage (n=15) and abdominal infection (n=8), but no digestive tract bleeding, intestinal fistula or digestive tract bleeding. After conservative therapy like enhanced peritoneal lavage, all patients survived from the post-operative complications. Of all patients, there were no long-term complications such as radiation enteritis and pancreatitis. The short-term post-operative complications like bile leakage and pancreatic leakage are quite common for pancreaticoduodenectomy. And there were no significant differences between the IORT group and non-IORT group.
Discussion
Our relevant research can be summarized as follows. First, we found that patients who did not received IORT had a higher probability of disease progression and poor outcomes. Second, we observed that IORT can effectively alleviate cancerous pain. Finally, there was no significant increase in additional complications in IORT patients.
Pancreatic cancer is characterized by the extremely malignant biological characteristics. Even in nowadays, there is only 20% of tumors can be resected at diagnosis, in which approximately 10-35% of patients may occur isolated local recurrences [7] [8] [9] , likely associated with positive microscopic resection margins. Our research shows that R1 margin status leads to the increased probability of overall progression and death. As Sugiura et. reported, R1 margins are indicative of biologically aggressive tumors [10] . Borderline resectable pancreatic cancer is in betweenness from resectability to technical unresectability, which is suffering with a higher recurrence rate for a fewer R0 ratio. So, it is necessary to stress the importance of attempting to achieve microscopically negative margins for curative intent. It should be mentioned that although several definitions have been projected for BRPC for example ASCO, we still selecting the NCCN CPG definition for its clearer criteria for tumor resection in contrast with ASCO [11] .
Available data in patients receiving IORT after pancreaticoduodenectomy suggest an improvement in local control. Alfieri et al. noted IORT in resectable pancreatic cancer increased local control and they found that local control was 58% in the IORT group vs. 29% in the group that did not receive IORT (p < 0.01) [12] . Reni et al reported that 127 patients of resectable pancreatic cancer surgically treated with curative intent combined with IORT was compared with 76 patients treated with surgery, in which median time to local failure treated with surgery alone or with IORT were 11 months and 14 months, respectively (p =0.02) [13] . In our research, the median PFS of IORT group is 13.7 months while the median PFS of IORT group is 8.9 months(p<0.01), suggusted that IORT combimed with surgery improves local control not only in resectable pancreatic cancer but also in borderline resectable pancreatic cancer. What's more, an Italian series evaluated 43 patients receiving IORT in addition to surgical resection whereas 47 underwent resection alone. Results revealed local recurrence in the group receiving IORT was 27% compared with 56% in the group receiving surgical resection alone (P <0.01). However, 1-year, 2-year and 3-year survival rates were respectively 71%, 24%, and 7% in IORT group and 49%, 16%, and 10% in non-IORT group (P was not significant), and there are no differences in overall survival [14] . The National Cancer Institute reported an experience evaluating 24 additional patients randomized to receive IORT (20 Gy). Excluding 7 perioperative deaths, an improvement in median survival was seen in the patients who received IORT (OS 18 vs. 12 months; P ¼ 0.01) [15] . Our research shows the OS in BRPC patients is 22.0 months in IORT group vs.14.8 months in non-IORT group (p<0.01). Whether the IORT can benefit the survival of patients in pancreatic cancer need to be further verified, but our study shows that IORT does improve the prognois of BRPC patients.
Many studies have documented pain control with IORT in locally advanced or unresectable pancreatic cancer, resulting in complete pain resolution in 75%-90% of cases [16] . Another research from China evaluated 43 patients with advanced pancreatic cancer who received IORT combined with EBRT. This approach was shown to alleviate pain, improve quality of life [12] . In our study, the rate of complete remission of pain in IORT group reaches to 86%, higher than the non-IORT group. The contrast showed IORT can control local pain in BRPC at same with locally advanced or unresectable pancreatic cancer. What is more, our research shows that no matter whether radical excision, patients improve the quality of life, away from the sideeffects of opioid painkillers. In our study, patients accept IORT with the INTRABEAM ® PRS500 system (Carl Zeiss Surgical, Oberkochen, Germany), which is a compact mobile X-ray source originally developed for intracranial stereotaxy in the early 1990s. is widely used in breast cancer nowadays. An analysis of 208 women who underwent IORT with INTRABEAM ® during breast conserving surgery (BCS) shows rare postoperative complications and the low immediate toxicity low without any grade 3/4 acute toxicity [17] . In resectable pancreatic adenocarcinoma, A larger series of 127 patients treated with potentially curative surgery and IORT comparing with a cohort of 76 patients who received surgery alone show no additional operative morbidity or mortality was seen with the addition of IORT [18] . In our study in borderline pancreatic adenocarcinoma, the application of radiotherapy with the Intrabeam ® device in selected patients has not resulted in increased perioperative morbidity or mortality.
For patients who present with border line resectable disease, neoadjuvant treatment strategies would be a better choice to enhance the odds of cure by improving rates of R0 resection. Research notes that neoadjuvant therapy would potentially benefit the BRPC patients [19] . Despite the encouraging clinical results of the neoadjuvant treatment for BRPC, there are also some problems we need to face with. On the one hand, it may cause radioactive enteritis and tissue edema surrounding tumor, therefore increase the odd of combined vascular resection and operation difficulty of some patients. On the other hand, part of patients with poor sensitivity would be failing to control the progression and delay the surgical treatment [20] . What is worth mentioning is, in order to exclude the effect of chemotherapy on the prognosis postoperatively, we deliberately selected patients receiving the gemcitabine-based combination chemotherapy.
In comparison with neoadjuvant treatment strategies aimed at borderline resectable disease, the results from this study suggest that IORT affords similar, if not better, outcomes. It is suitable for patients who are not willing to accept neoadjuvant chemotherapy in China especially. For most of patients with BRPC, surgical resection combined with IORT will help to achieve progressionfree survival benefit and improve their quality of life. The addition of IORT after surgery did not increase rates of perioperative mortality, postoperative complications and in-hospital deal significantly. In our institution, the radiation dose was similar to the dose of most of IORT for pancreatic cancer in the worldwide. The cost of the addition of IORT is much cheaper than the cost of neoadjuvant therapy like neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] .
Conclusion
In conclusion, receiving IORT after surgical pancreaticoduodenectomy shows a high rate of R0 resection, improves local control and prolongs survival. This modality was relatively safe and cost-effective. What is more, it could relief the abdominal/waist pain of BRPC patients, keep patients away from the by-effects of opioid painkillers and improve the quality of life. This study supports the design of III prospective RCT trial for borderline pancreatic cancer. In our institution, IORT has routinely been used in the management of part of patients with BRPC.
